fr

EN DE

fr

EN DE

Publications

2108 PUBLICATIONS - effacer la recherche

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

2021

Cancers

Galland L

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer.

2021

Nature communications

Uyanik B

Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.

2021

European journal of cancer (Oxford, England : 1990)

Breton C

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

2021

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Falcoz PE

Does functional evaluation before lung cancer surgery need reappraisal?

2021

European radiology

Pelissier M

Maximum slope using ultrafast breast DCE-MRI at 1.5 Tesla: a potential tool for predicting breast lesion aggressiveness.

2021

Breast (Edinburgh, Scotland)

Mamguem Kamga A

Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.

2021

Clinical radiology

Autrusseau PA

Pain relief and local tumour control following percutaneous image-guided cryoablation for spine metastasis: a 12-year single-centre experience.

2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Sastre-Garau X

A NGS-based Blood Test for the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization.

2021

The British journal of dermatology

Guillaume T

Cemiplimab-rwlc in Advanced Cutaneous Squamous Cell Carcinoma: a real-life experience in a French Dermatology Department.

2021

Journal of medicinal chemistry

Renard E

Positron Emission Tomography Imaging of Neurotensin Receptor-Positive Tumors with Ga-Labeled Antagonists: The Chelate Makes the Difference Again.